Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells

Interstitial lung disease (ILD) is a common pulmonary manifestation of idiopathic inflammatory myopathy (IIM). The overall 5-year mortality is 50%. The prognosis is poor and the treatment is

fibrosis
interstitial lung disease
ciclosporin
pulmonary fibrosis
tacrolimus
  • 0 views
  • 30 Nov, 2021
  • 1 location
Partitioned Training of Patients With Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a lung disease that limits the ability to breathe enough for a good workout. One way to improve the exercise training is to reduce the number of muscles being trained together. By training one leg at a time, the patient does not have to breathe …

  • 0 views
  • 24 Mar, 2022
  • 1 location
Assessment of Continuous Positive Airway Pressure Therapy in IPF (ACT-IPF)

The purpose of this study is to evaluate whether biomarkers of lung injury and remodeling are responsive to effective continuous positive airway pressure (CPAP) treatment in adults with idiopathic pulmonary fibrosis (IPF) and moderate-to-severe obstructive sleep apnea (OSA).

idiopathic pulmonary fibrosis
fibrosis
pulmonary fibrosis
  • 0 views
  • 13 Apr, 2022
  • 1 location
Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis

We conduct this study to investigate the efficacy of triple therapy (high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor) compared with dual-therapy regimens (high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor) and whether it reduces the risk of poor pulmonary prognosis in patients with moderate to high risk anti-MDA5+ DM.

  • 0 views
  • 04 Jun, 2022
  • 1 location
The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease

Interstitial lung disease (ILD) is the result of over 200 etiological pathways arising from several different insults to the lung parenchyma: inhaled substances, drug side effects, connective

fibrosis
pulmonary fibrosis
pulmonary disease
sarcoidosis
cancer
  • 81 views
  • 28 Jun, 2022
  • 3 locations
FAPI PET for Lung Fibrosis (FAPI ILD)

This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the

lung biopsy
ct scan
fibrosis
pulmonary fibrosis
pneumonia
  • 0 views
  • 30 May, 2022
  • 1 location
Comparison of PR Efficiency in Home-based With Hospital-based PR in Bronchiectasis

The investigators aimed to compare the home-based Pulmonary Rehabilitation with the hospital-based pulmonary rehabilitation in terms of pulmonary rehabilitation efficiency in patient with bronchiectasis.

pulmonary rehabilitation
bronchiectasis
  • 12 views
  • 26 Apr, 2022
  • 1 location
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension (SAPPHIRE)

This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.

chest radiograph
fibrosis
pulmonary disease
sarcoidosis
hypertension
  • 14 views
  • 26 Feb, 2022
  • 1 location
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 (ENDCOV-I)

This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of Nintedanib on slowing the rate of lung disease in patients who have been diagnosed with COVID-19, and have ongoing …

fibrosis
interstitial lung disease
assisted ventilation
nintedanib
bronchiectasis
  • 0 views
  • 05 May, 2022
  • 8 locations
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest

Obstructive Pulmonary Disease (COPD), Interstitial Lung Disease (ILD), and Pulmonary Hypertension (PH) patients during rest. Subjects will be titrated from 0 L/min until they maintain 95% SpO2 for each of the

forced expiratory volume
chronic obstructive pulmonary disease
pulmonary function test
respiratory disease
pulmonary disease
  • 0 views
  • 17 Dec, 2021
  • 2 locations